Y-mAbs Therapeutics, Inc. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Y-mAbs TherapPRNewsWire • 02/14/23
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - YMABNewsfile Corp • 02/11/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Y-mAbs Therapeutics, Inc. - YMABNewsfile Corp • 02/10/23
ROSEN, LEADING INVESTOR COUNSEL, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMABPRNewsWire • 02/10/23
Y-mAbs Class Action: Levi & Korsinsky Reminds Y-mAbs Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 20, 2023 - YMABNewsfile Corp • 02/09/23
YMAB INVESTOR NOTICE: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact Firm's Attorneys, Securities Fraud Class Action PendingNewsfile Corp • 02/08/23
Y-mAbs Therapeutics Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More InformationNewsfile Corp • 02/08/23
YMAB LOSS ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMABNewsfile Corp • 02/08/23
ROSEN, A Leading Law Firm, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMABNewsfile Corp • 02/07/23
Y-mAbs Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 20, 2023 to Discuss Your Rights - YMABNewsfile Corp • 02/06/23
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMABNewsfile Corp • 02/03/23
SHAREHOLDER ACTION NOTICE: Scott+Scott Attorneys at Law LLP Reminds Investors That a Securities Class Action Has Been Filed Against Y-mAbs Therapeutics, Inc. (YMAB) Lead Plaintiff Deadline is March 20, 2023Newsfile Corp • 02/03/23
ROSEN, Top Ranked Investor Counsel, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMABNewsfile Corp • 02/02/23
Y-mAbs and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for NaxitamabGlobeNewsWire • 02/02/23
Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) Investors and Encourages Investors to Contact the Firm Before March 20, 2023Business Wire • 02/01/23
YMAB CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact the Firm's Attorneys, Securities Fraud Lawsuit FiledNewsfile Corp • 02/01/23
SHAREHOLDER ACTION REMINDER: Scott+Scott Attorneys at Law LLP Reminds Investors That a Securities Class Action Has Been Filed Against Y-mAbs Therapeutics, Inc. (YMAB)Newsfile Corp • 01/31/23
ALERT: Investors in Y-mAbs Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - YMABNewsfile Corp • 01/31/23
ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMABPRNewsWire • 01/30/23
DEADLINE: Investors in Y-mAbs Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - YMABPRNewsWire • 01/28/23
Y-MABS THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. - YMABPRNewsWire • 01/28/23
Y-mAbs Therapeutics, Inc. (YMAB) Investor Alert: Robbins LLP Reminds Shareholders of Class Action Against Y-mAbs Therapeutics, Inc.Business Wire • 01/27/23
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Y-mAbs Therapeutics, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 01/27/23
YMAB LAWSUIT: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact the Firm's Attorneys, Securities Fraud Class Action FiledNewsfile Corp • 01/26/23
